TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large growth in short interest in May. As of May 15th, there was short interest totalling 109,000 shares, a growth of 206.2% from the April 30th total of 35,600 shares. Currently, 0.7% of the company's stock are short sold. Based on an average daily volume of 49,800 shares, the short-interest ratio is presently 2.2 days.
TriSalus Life Sciences Trading Down 0.9%
Shares of NASDAQ TLSI traded down $0.05 during mid-day trading on Friday, reaching $5.43. The company had a trading volume of 50,544 shares, compared to its average volume of 42,313. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $7.55. The stock has a market cap of $205.47 million, a P/E ratio of -2.18 and a beta of 0.50. The firm has a 50 day simple moving average of $5.42 and a two-hundred day simple moving average of $5.09.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to the consensus estimate of $9.04 million. During the same period in the previous year, the company earned ($0.60) EPS. On average, equities analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current year.
Insider Buying and Selling at TriSalus Life Sciences
In related news, insider Richard Marshak sold 6,597 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the sale, the insider now owns 69,101 shares of the company's stock, valued at $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 16,125 shares of company stock valued at $83,528 in the last quarter. Corporate insiders own 27.50% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in shares of TriSalus Life Sciences in the first quarter valued at approximately $187,000. Charles Schwab Investment Management Inc. purchased a new stake in TriSalus Life Sciences in the 1st quarter valued at $55,000. Connective Capital Management LLC acquired a new stake in TriSalus Life Sciences during the 4th quarter worth $140,000. Bridgeway Capital Management LLC boosted its stake in TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock worth $326,000 after purchasing an additional 50,000 shares during the period. Finally, Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% during the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.
Analyst Ratings Changes
TLSI has been the topic of a number of analyst reports. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a "buy" rating and a $10.00 price objective on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $10.75.
Get Our Latest Stock Analysis on TLSI
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Articles
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
